Pharmaceutical News and Articles

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

Celldex Therapeutics, Inc. (NASDAQ CLDX) announced today positive results from the Company s Phase 2 clinical trial of barzolvolimab in two of the most common f

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma

FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

Many Seniors at Risk for Financial Precarity From Cost of Hospital Stay

Many Medicare beneficiaries are at risk for financial hardship from the costs of a single hospital stay, according to a study published online Oct. 29 in the An

Healthy Eating Index 2015 Score Linked to Overactive Bladder

There is a positive association between a higher Healthy Eating Index (HEI)-2015 score and overactive bladder (OAB), according to a study published online Sept.

Female Pediatricians Earn About 93 Percent of Male Pediatricians

Female pediatricians earn about 93 percent of what male pediatricians earn, according to a study published online Oct. 29 in Pediatrics.Mary Pat Frintner, M.S.P

ED Visit Rate 36.1 per 1,000 Older Adults With Alzheimer Disease

For adults aged 65 years and older with Alzheimer disease, the emergency department visit rate was 36.1 visits per 1,000 adults in 2020 to 2022, according to an

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with Keytruda (pembrolizumab) After Neoadjuvant Keytruda and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Merck (NYSE MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq MRNA), today announced the initiation of INTerpath-009, a pivo